KRAS and colorectal carcinoma: Although both MEK and RAF inhibitor monotherapy are less promising in KRAS-mutant CRC, the combination of these two inhibitors demonstrated synergy in preclinical models of KRAS-mutant CRC cell lines [110, 111].